Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

This study is testing a new drug called TU2218 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors. TU2218 is designed to block pathways that allow cancer cells to suppress the immune system. The goal is to restore the immune system's ability to recognize and destroy cancer cells. **You may be eligible if:** - You are 18 years old or older with a life expectancy of at least 12 weeks - You have an advanced solid tumor that is not surgically removable and has not responded to or progressed on standard treatments - You have measurable disease and are in good enough health to participate (ECOG 0–1) - You can swallow capsules **You may NOT be eligible if:** - You are not in adequate general health (ECOG 2 or higher) - Your cancer has not progressed on prior PD-1/PD-L1 immunotherapy (for certain phases of the study) - You have conditions preventing you from safely receiving the study drugs Talk to your doctor to see if this trial is right for you.